NVONYQHealthcare·Drug Manufacturers - General#9 in industry

Novo Nordisk A/S

Reports in 9d· 2026-05-06

-34.1% · 90d

$41.45

+0.28 (+0.68%)

News

No News Yet

Press releases and SEC filings for NVO will appear here as they are published.

Check back later for updates

Key Data

Market Cap$183.85B

Open$40.76

Prev Close$41.17

Day Range$40.55 – $41.66

52W Range$35.12 – $81.44

Volume14,405,169

P/E (TTM)11.48

EPS$3.61

Dividend Yield4.38%

Beta0.27

Profit Margin33.14%

Revenue Growth-7.60%

Price Target$46.65(+12.5%)

Next Earnings2026-05-06(9d)

Analyst Ratings

Buy14 analysts

Buy 5Hold 9Sell 0

About

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Healthcare · Drug Manufacturers - General

68,794 employees

www.novonordisk.com